Catalio Capital has survived choppy years in the sector and returned more than $300mn to its limited partners
Acquisition is latest example of western drugmakers turning to China to tap innovation
Once-hyped genetic start-up issues latest guidance after reporting further quarterly revenue declines
Initiative is part of growing international efforts to give early warning of pandemic threats
Scheme calls for closed military zone and evacuation, with those remaining denied aid
Once-hyped genetic testing company hit by data breach, plunging share price and board resignations
Losses widen at Isomorphic Labs, as new Nobel Prize winner pushes forward with effort to use AI in healthcare
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
Joe Kiani asserts in a California lawsuit that he is entitled to severance under provisions typically tied to a company sale
European Court of Justice says European Commission had no right to investigate tie-up
Pandemic winners BioNTech and Moderna face hurdles as they seek to bring their groundbreaking technology to oncology
Decision a setback for Lykos Therapeutics and psychedelic treatment aimed at 13mn Americans with PTSD
Sergey Brin’s non-profit funds research into using hallucinogen for mental health treatment
Incubator Flagship Pioneering plans to finance and launch array of companies using AI for pharmaceutical development
Sale of most of FairJourney Biologics means London-based owner GHO Capital realises close to 10-fold return
Discovery could allow more precise and efficient targeting of DNA modifications
Vutrisiran injection cut risk of death and adverse cardiovascular events by at least 28%, company says
Shares of biotech Sarepta soar 40% after approval for most expensive treatment in the world
Shares in cancer-test developer trading in low volumes ahead of spin-off demanded by antitrust regulators
Critics of plan include green activists, farmers, biotech start-ups and multinationals
Two developers of drugs for inflammatory diseases are latest to disregard poor performance of newly listed companies
Non-binding vote on psychedelic drug will carry weight with FDA in blow to pharmaceutical developers
US decision hands biotech group its first regulatory blessing since its blockbuster Covid-19 jab
US group hopes EyeBio will refill its pipeline with treatments targeting causes of blindness
